Created at	Source	Raw Value	Validated value
Oct. 26, 2020, 11:31 p.m.	usa	Phase 1: Occurrence of adverse events and Serious Adverse events;Phase 2: Evaluation of Neutralizing Antibody Titers	Phase 1: Occurrence of adverse events and Serious Adverse events;Phase 2: Evaluation of Neutralizing Antibody Titers